Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors’ Liability Premiums
  • Florida’s KidCare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors' Liability Premiums
  • Florida’s KidCare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Aug 8 2016

Full Issue

Lung Cancer Patients Travel To Cuba For Novel Drug Not Approved In U.S.

The risk comes with high costs, but a small number of Americans have seen results. In other news, The Boston Globe reports on what happens to cancer research when a lab shuts down. And, news outlets cover other developments including hormone therapy risks for prostate cancer patients, a breast cancer research connection to dogs, cellphone radiation exposure, immunotherapy and a mother's hard decision to stop treatment.

Even as the US-Cuba relationship changes, bringing a growing numbers of tourists, the island remains in many ways frozen in time; when (Mick) Phillips was last there in the spring, he was driven around by a cabbie in a ‘55 Buick. But a striving, modern biotech enterprise thrives in Cuba, too. It’s a legacy of the US embargo: With drugs from the US unavailable, Cuba had to develop its own pharmaceutical industry. Among its biggest accomplishments is a novel treatment for lung cancer called CimaVax. (Waters, 8/5)

Lynn Hlatky has spent her career as a scientist studying the development of cancer, hoping in some way to improve understanding of an insidious disease.She took a path common in her field: won funding, established a lab, assembled a team of colleagues, and got to work.But now, a decade of Hlatky’s work is suddenly gone. After a highly unusual chain of events, thousands of little glass tubes of cells and proteins, pieces of human tumor tissue, and other biological samples have been destroyed.The materials fell victim to the bankruptcy of Genesys Research Institute Inc., a nonprofit that in 2013 took control of Hlatky’s lab on the campus of St. Elizabeth’s Medical Center in Brighton. (McCluskey, 8/6)

Black men treated with hormone therapy for prostate cancer may have a higher risk of death than white men undergoing the same therapy, according to a new study. But the deaths aren’t actually caused by prostate cancer. Androgen deprivation therapy, or ADT, is a hormone treatment that shrinks prostate tumors. Researchers from the Brigham and Women’s Hospital in Boston found that black men undergoing the therapy had a 77 percent higher risk of death than non-black men. (Beachum, 8/5)

Through the Shelter Canine Mammary Tumor Program, breast tumors are removed from homeless dogs that would otherwise go untreated and quite likely die. The dogs are then put up for adoption.At the same time, the dogs and their tumors are contributing to research on breast cancer in humans... Shelter dogs turn out to be excellent subjects for the study of how breast cancers form. (Giordano, 8/7)

Concerns about the potential harmful effects of radiofrequency radiation have dogged mobile technology since the first brick-sized cellphones hit the market in the 1980s. Industry and federal officials have largely dismissed those fears, saying the radiation exposure is minimal and that the devices are safe. ... But the launch of super-fast 5G technology over the next several years will dramatically increase the number of transmitters sending signals to cellphones and a host of new Internet-enabled devices, including smart appliances and autonomous vehicles. (Puzzanghera, 8/8)

Advancements in immunotherapy are giving Rome oncologist Dr. Melissa Dillmon hope that even more people will survive their battles with cancer. She told the Rotary Club of Rome on Thursday immunotherapy was pioneered to treat melanoma, but is now approved to fight lung, kidney and bladder cancers. She thinks its use will continue to spread. (Walker, 8/5)

More than a decade ago, Colleen Lum was diagnosed with Stage 3 ovarian cancer. ...A few months ago, after battling the disease for 13 years, Lum, who lives with her husband and family in Hopedale, Massachusetts, decided to end treatment. Today, at age 56, her health has further declined, according to her daughter. Lum is no longer eating or drinking much. (Brewster and Meyer, 8/5)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ